Pain News and Research

Latest Pain News and Research

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

ISTA third quarter net revenue increases 31% to $42.0 million

ISTA third quarter net revenue increases 31% to $42.0 million

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Icagen awarded $733,000 of federal government grants

Icagen awarded $733,000 of federal government grants

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

FDA selects Rochester to lead initiative to identify improved pain treatments

FDA selects Rochester to lead initiative to identify improved pain treatments

New REACT medical trial for early diagnosis of lung cancer

New REACT medical trial for early diagnosis of lung cancer

FDA announces partnership agreement with University of Rochester to form ACTION Initiative

FDA announces partnership agreement with University of Rochester to form ACTION Initiative

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Dr Sartori’s contentious alternative therapy: inquest date set

Dr Sartori’s contentious alternative therapy: inquest date set

AHRQ: Hospital admissions for adverse drug reactions have doubled

AHRQ: Hospital admissions for adverse drug reactions have doubled

Endo third quarter total revenues increase 23% to $444.1 million

Endo third quarter total revenues increase 23% to $444.1 million

American Anesthesiology acquires Greensboro Anesthesia Physicians

American Anesthesiology acquires Greensboro Anesthesia Physicians

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

NeurAxon’s NXN-188 compound effective for acute migraine treatment

NeurAxon’s NXN-188 compound effective for acute migraine treatment

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.